Evaluating outcomes associated with revised fluoroquinolone breakpoints for Enterobacterales urinary tract infections: A retrospective cohort study

Keyphrases

• Retrospective Cohort Study 100%
• Fluoroquinolones 100%
• Enterobacterales 100%
• Urinary Tract Infection 100%
• Minimum Inhibitory Concentration 100%
• Levofloxacin 45%
• Ciprofloxacin 45%
• Infection Recurrence 27%
• Recurrent Urinary Tract Infections (rUTIs) 18%
• Adult Patients 9%
• Study Support 9%
• Multivariable 9%
• Clinic Visits 9%
• Hospital Admission 9%
• Emergency Department Visits 9%
• Antibiotic Prescription 9%
• Risk Factors for Urinary Tract Infection 9%
• Emergency Clinic 9%
• Respiratory Disorders 9%
• Interpretation Criteria 9%

Pharmacology, Toxicology and Pharmaceutical Science

• Quinolone Derivative 100%
• Cohort Study 100%
• Urinary Tract Infection 100%
• Minimum Inhibitory Concentration 100%
• Levofloxacin 45%
• Ciprofloxacin 45%
• Infectious Agent 27%
• Recurrent Disease 27%
• Respiratory Tract Disease 9%
• Antibiotics 9%
• Retrospective Study 9%

Immunology and Microbiology

• Minimum Inhibitory Concentration 100%
• Enterobacterales 100%
• Urinary Tract 100%
• Infectious Agent 27%